Compare GNLX & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLX | RVLV |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.4M | 2.1B |
| IPO Year | 2023 | 2019 |
| Metric | GNLX | RVLV |
|---|---|---|
| Price | $2.72 | $31.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $19.75 | ★ $26.42 |
| AVG Volume (30 Days) | 140.7K | ★ 1.1M |
| Earning Date | 11-05-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.78 |
| EPS | N/A | ★ 0.78 |
| Revenue | N/A | ★ $1,195,039,000.00 |
| Revenue This Year | N/A | $8.95 |
| Revenue Next Year | N/A | $6.42 |
| P/E Ratio | ★ N/A | $40.27 |
| Revenue Growth | N/A | ★ 9.24 |
| 52 Week Low | $1.99 | $16.80 |
| 52 Week High | $8.54 | $33.68 |
| Indicator | GNLX | RVLV |
|---|---|---|
| Relative Strength Index (RSI) | 21.34 | 67.62 |
| Support Level | $3.32 | $29.56 |
| Resistance Level | $4.99 | $31.48 |
| Average True Range (ATR) | 0.35 | 1.05 |
| MACD | -0.10 | -0.07 |
| Stochastic Oscillator | 4.07 | 86.49 |
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.